NUCLEAR AND TRANSGOLGI TARGETING AND MEMBRANE INDUCTION BY DENGUE NS5 RNA-DEPENDENT RNA POLYMERASE INTERDOMAIN REGION
Funder
National Health and Medical Research Council
Funding Amount
$450,750.00
Summary
Dengue virus is the causative agent of a mosquito-borne disease, Dengue fever, relevant to northern Queensland, where antibodies from a previous infection can complex with virus of a different serotype in a subsequent infection, and cause a severe, potentially fatal form of the disease (Dengue haemorrhagic fever-Dengue shock syndrome). The present proposal seeks to further understanding of the role of the dengue RNA-dependent RNA polymerase NS5, which is essential for viral RNA replication, with ....Dengue virus is the causative agent of a mosquito-borne disease, Dengue fever, relevant to northern Queensland, where antibodies from a previous infection can complex with virus of a different serotype in a subsequent infection, and cause a severe, potentially fatal form of the disease (Dengue haemorrhagic fever-Dengue shock syndrome). The present proposal seeks to further understanding of the role of the dengue RNA-dependent RNA polymerase NS5, which is essential for viral RNA replication, within the viral infectious cycle. We intend to examine the subcellular targeting properties of a short central region (the interdomain) of NS5, which appears to play multiple roles in targeting to both the perinuclear Golgi-membranes and to the nucleus, as well as in inducing intracellular membranes derived from the Golgi which are the site of viral replication. We will determine how NS5 localisation-membrane induction may differ in insect and primate cells, and attempt to isolate binding partners of NS5 from the nucleus and Golgi compartment of insect and primate cells using various different approaches. Our studies should assist in understanding NS5's critical role in the Dengue infectious cycle, and contribute towards devising new anti-viral strategies such as vaccination and-or therapies targeted at the NS5 interdomain.Read moreRead less
I am a molecular and cell biologist with a major research focus on haemopoiesis and leukaemia development. This work principally involves the analysis of mutant mouse models.
Nanomedicines Immunotargeting: Hitting The Target Or Lost In Translation ?
Funder
National Health and Medical Research Council
Funding Amount
$413,042.00
Summary
Nanomedicines are some of the most exciting novel approaches to improving the way we detect, manage and treat cancers. This cross-disciplinary project aims to provide a rigorous understanding of how nanomedicines penetrate solid tumour tissues. To validate in vitro tumour model developed in the project, in vivo studies will be carried out in a mice model. The penetration and distribution of nanomedicines inside tumour tissues after intravenous administration will be determined.
I am a structural biologist investigating the molecular control of cell death. Atomic resolution structural data are used to guide the discovery of new drugs.
Schistosomiasis is one of the world's most serious and prevalent diseases affecting nearly 200 million people world-wide. It is currently treated with a single drug, though there is growing concern about the development of resistance to it. In this proposal we will explore whether a new cellular pathway involving the cell death machinery we have identified in the disease-causing parasites could provide a possible target for the development of new treatments against schistosomiasis.
Molecular Characterisation Of The DBHS Proteins In Telomerase Assembly
Funder
National Health and Medical Research Council
Funding Amount
$686,246.00
Summary
Telomerase is an enzyme that is active in over 90% of cancers. Telomerase activity allows cancer cells to divide an indefinite number of times. We have identified a novel role for the DBHS protein family in regulating telomerase activity. We aim to investigate the mechanisms by which these proteins function to assemble and transport telomerase to its site of action in the cell. We then aim to develop chemical inhibitors of these proteins, and test their utility in preventing cancer cell growth.